Margaret G. Mcglynn - Apr 8, 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
Director
Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Apr 8, 2022
Transactions value $
-$763,380
Form type
4
Date filed
4/12/2022, 04:05 PM
Previous filing
Apr 4, 2022
Next filing
May 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Options Exercise $638K +5K +454.96% $127.54 6.1K Apr 8, 2022 Direct
transaction VRTX Common Stock Sale -$1.37M -4.9K -80.34% $280.19 1.2K Apr 8, 2022 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$28.1K -100 -8.34% $281.49 1.1K Apr 8, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VRTX Stock Option (Right to Buy) Options Exercise $0 -5K -50% $0.00 5K Apr 8, 2022 Common Stock 5K $127.54 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Ms. McGlynn's company approved trading plan under Rule 10b5-1.
F2 Ms. McGlynn undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $280.19 (range $280.00 to $280.95).
F4 Fully vested.